Patient values and preferences regarding communicating risk versus benefit of benzodiazepine initiation: A cross-sectional survey study.

Karn Chahal, Matthew Glass, Jamie Falk, Alexander Singer, Christine Leong
Author Information
  1. Karn Chahal: College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada.
  2. Matthew Glass: College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada.
  3. Jamie Falk: College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada.
  4. Alexander Singer: Department of Family Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada.
  5. Christine Leong: College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada. ORCID

Abstract

Background and Aims: Communicating information about the risks and benefits of benzodiazepines so that it is meaningful to the patient has not been previously described. This study aims to determine patient preferences regarding information received before initiating a benzodiazepine.
Methods: An online survey was distributed through social media and advertisements to Canadians ≥18 years old over a 6-month period (May-Oct 2022) to collect participant's rating of importance of statements and factors about the risk and benefits of benzodiazepines before initiating treatment using a 10-point Likert-type scale. Treatment preferences based on efficacy and risk information were also elicited. The survey was developed and pilot-tested in collaboration with an advisory committee of individuals with lived and living experience with benzodiazepine use.
Results: Thirty-seven participants responded to the survey (mean age 30 years old, 81.1% identified as female). The majority of respondents had a history of anxiety (83.8%) or insomnia (32.4%), and 10 (27.0%) respondents had used a benzodiazepine. Patient counseling related to withdrawal symptoms of benzodiazepines, risk of harm in combination with other sedating agents, risk of physical and psychological dependence, and risk of effects on cognition were rated high in the importance of receiving this information before starting a benzodiazepine relative to efficacy endpoints, such as improvement in sleep parameters. When provided with information about the chance of efficacy and risk of harm, 100% would have selected cognitive behavioral therapy as the best treatment option. The most frequently reported source of medication information where patients have sought information was from the internet (25.0%), followed by doctors (21.9%) and pharmacists (18.8%).
Conclusions: This study identified patient important factors and statements viewed as important to communicate before initiating a benzodiazepine. The findings of this survey study will help inform decision-making when considering treatment options for managing anxiety or insomnia.

Keywords

References

  1. Can J Aging. 2010 Jun;29(2):205-13 [PMID: 20420748]
  2. BMC Med Inform Decis Mak. 2013;13 Suppl 2:S8 [PMID: 24625261]
  3. Int J Environ Res Public Health. 2021 Sep 28;18(19): [PMID: 34639523]
  4. Can J Clin Pharmacol. 2003 Summer;10(2):72-7 [PMID: 12879145]
  5. Health Sci Rep. 2023 Dec 01;6(12):e1597 [PMID: 38045626]
  6. JAMA Psychiatry. 2015 Feb;72(2):136-42 [PMID: 25517224]
  7. CNS Drugs. 2009;23(1):19-34 [PMID: 19062773]
  8. Br J Psychiatry. 2014 Jun;204(6):471-9 [PMID: 24526745]
  9. Br J Addict. 1987 Dec;82(12):1317-27 [PMID: 2892523]
  10. J Am Geriatr Soc. 2003 May;51(5):671-7 [PMID: 12752843]
  11. Drugs Aging. 2013 Oct;30(10):793-807 [PMID: 23912674]
  12. Expert Opin Drug Saf. 2014 Jul;13(7):919-34 [PMID: 24905348]
  13. Psychiatr Serv. 2016 Sep 1;67(9):1012-8 [PMID: 27133727]
  14. BMJ. 2016 Jun 03;353:i2893 [PMID: 27260319]
  15. BMJ. 2012 Jun 18;344:e3996 [PMID: 22709962]
  16. Health Sci Rep. 2019 Feb 21;2(5):e116 [PMID: 31139756]
  17. Annu Rev Public Health. 2003;24:413-33 [PMID: 12428034]
  18. Can J Clin Pharmacol. 2001 Winter;8(4):213-21 [PMID: 11743594]
  19. Ther Adv Psychopharmacol. 2022 Apr 25;12:20451253221082386 [PMID: 35499041]
  20. Medwave. 2018 Jan 30;18(1):e7159 [PMID: 29385122]
  21. JAMA Intern Med. 2014 Jun;174(6):890-8 [PMID: 24733354]
  22. J Clin Psychiatry. 1999 Sep;60(9):604-12 [PMID: 10520979]
  23. Epidemiol Psichiatr Soc. 2009 Jul-Sep;18(3):248-54 [PMID: 20034203]

Word Cloud

Created with Highcharts 10.0.0informationriskbenzodiazepinesurveybenzodiazepinespatientstudypreferencesinitiatingtreatmentefficacymedicationbenefitsregardingyearsoldimportancestatementsfactorsidentifiedrespondentsanxiety8%insomnia0%PatientcounselingharmimportantBackgroundAims:CommunicatingrisksmeaningfulpreviouslydescribedaimsdeterminereceivedMethods:onlinedistributedsocialmediaadvertisementsCanadians≥186-monthperiodMay-Oct2022collectparticipant'sratingusing10-pointLikert-typescaleTreatmentbasedalsoeliciteddevelopedpilot-testedcollaborationadvisorycommitteeindividualslivedlivingexperienceuseResults:Thirty-sevenparticipantsrespondedmeanage30811%femalemajorityhistory83324%1027usedrelatedwithdrawalsymptomscombinationsedatingagentsphysicalpsychologicaldependenceeffectscognitionratedhighreceivingstartingrelativeendpointsimprovementsleepparametersprovidedchance100%selectedcognitivebehavioraltherapybestoptionfrequentlyreportedsourcepatientssoughtinternet25followeddoctors219%pharmacists18Conclusions:viewedcommunicatefindingswillhelpinformdecision-makingconsideringoptionsmanagingvaluescommunicatingversusbenefitinitiation:cross-sectionaldecision‐making

Similar Articles

Cited By